Advertisement

Cigarette Smoking and Antiplatelet Effects of Aspirin Monotherapy Versus Clopidogrel Monotherapy in Patients with Atherosclerotic Disease: Results of a Prospective Pharmacodynamic Study

  • Fabiana Rollini
  • Francesco Franchi
  • Jung Rae Cho
  • Christopher DeGroat
  • Mona Bhatti
  • Elisabetta Ferrante
  • Ronakkumar Patel
  • Andrew Darlington
  • Antonio Tello-Montoliu
  • Bhaloo Desai
  • JoséLuis Ferreiro
  • Ana Muniz-Lozano
  • Martin M. Zenni
  • Luis A. Guzman
  • Theodore A. Bass
  • Dominick J. AngiolilloEmail author
Article

Abstract

Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects. However, to date, all PD studies have been conducted in patients on dual antiplatelet therapy with aspirin and clopidogrel, and it is unknown whether clopidogrel monotherapy can offer more effective antithrombotic effects compared with aspirin alone among smoking patients. Sixty aspirin-treated (81 mg/day) patients with vascular disease, classified as nonsmokers, light smokers, and heavy smokers according to cotinine serum levels, were enrolled. Patients were switched to clopidogrel (75 mg/day) monotherapy for 7–10 days. PD assessments were performed before and after switch by multiple electrode aggregometry (MEA) and kaolin-activated thromboelastography (TEG). Complete PD data were obtained in 57 patients (nonsmokers, n = 27; light smokers, n = 13; heavy smokers, n = 17). On treatment platelet reactivity following MEA, adenosine diphosphate (ADP) + prostaglandin E1 (PGE1) and thrombin receptor-activating peptide (TRAP) stimuli were significantly lower among heavy smokers following switch to clopidogrel. A significant inverse effect was observed with MEA arachidonic acid (ASPI), while neutral findings were shown with MEA collagen (COLL) stimulus. Thrombin and fibrin activity assessed by clot generation parameters were all nonsignificantly different but showed trends towards enhanced antithrombotic activity with clopidogrel among heavy smokers. In heavy smokers with vascular disease manifestations, clopidogrel is associated with enhanced platelet inhibitory effects, affecting purinergic and non-purinergic pathways, compared with aspirin as measured by MEA. Moreover, among smokers, clopidogrel offers trends towards enhanced effects on parameters of clot generation measured by TEG.

Keywords

Smoking Platelets Thrombus Aspirin Clopidogrel 

Notes

Acknowledgments

The present study was funded by an institutional grant of the University of Florida College of Medicine-Jacksonville and by a grant provided by the James and Esther King Biomedical Research Program (1KN01-33989).

Conflict of Interest

Conflict of interest forms will be submitted offline.

Fabiana Rollini has no conflict of interest to report.

Francesco Franchi has no conflict of interest to report.

Jung Rae Cho has no conflict of interest to report.

Christopher DeGroat has no conflict of interest to report.

Mona Bhatti has no conflict of interest to report.

Elisabetta Ferrante has no conflict of interest to report.

Ronakkumar Patel has no conflict of interest to report.

Andrew Darlington has no conflict of interest to report.

Antonio Tello-Montoliu has no conflict of interest to report.

Bhaloo Desai has no conflict of interest to report.

José Luis Ferreiro received payment as an individual for (a) honoraria for lectures from Eli Lilly Co; Daiichi Sankyo, Inc.; and Astra Zeneca and (b) consulting fees from Astra Zeneca and Eli Lilly Co.

Ana Muniz-Lozano has no conflict of interest to report.

Martin M. Zenni has no conflict of interest to report.

Luis A. Guzman has no conflict of interest to report.

Theodore A. Bass has no conflict of interest to report.

Dominick J. Angiolillo received payment as an individual for (a) consulting fee or honorarium from Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Merck, Evolva, Abbott Vascular, and PLx Pharma; (b) Participation in review activities from Johnson & Johnson, St. Jude, and Sunovion; and (c) institutional payments for grants from Bristol Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Otsuka, Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca, Evolva, and Gilead and has other financial relationships with Esther and King Biomedical Research Grant.

References

  1. 1.
    Cigarette smoking among adults: United States, 2006. (2007). MMWR Morb Mortal Wkly Rep, 56, 1157–1161.Google Scholar
  2. 2.
    Ockene, I. S., & Miller, N. H. (1997). Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association: American Heart Association Task Force on Risk Reduction. Circulation, 96, 3243–3247.PubMedCrossRefGoogle Scholar
  3. 3.
    Ambrose, J. A., & Barua, R. S. (2004). The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol, 43, 1731–1737.PubMedCrossRefGoogle Scholar
  4. 4.
    Mangiacapra, F., & Barbato, E. (2013). Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res, 6, 310–315.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhao, Z. G., Chen, M., Peng, Y., Chai, H., Liu, W., Li, Q., Ren, X., Wang, X. Q., Luo, X. L., Zhang, C., Huang, D. J. (2013). The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart Jun 8. [Epub ahead of print].Google Scholar
  6. 6.
    Gagne, J. J., Bykov, K., Choudhry, N. K., Toomey, T. J., Connolly, J. G., & Avorn, J. (2013). Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ, 347, f5307.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Gurbel, P. A., Nolin, T. D., & Tantry, U. S. (2012). Clopidogrel efficacy and cigarette smoking status. JAMA, 307, 2495–2496.PubMedCrossRefGoogle Scholar
  8. 8.
    Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., & Sabatine, M. S. (2009). Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol, 53, 1273–1278.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Berger, J. S., Bhatt, D. L., Steinhubl, S. R., Shao, M., Steg, P. G., Montalescot, G., Hacke, W., Fox, K. A., Lincoff, A. M., Topol, E. J., Berger, P. B., & CHARISMA Investigators. (2009). Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation, 120, 2337–2344.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mehta, S. R., Tanguay, J. F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H. J., Budaj, A., Avezum, A., Widimsky, P., Steg, P. G., Bassand, J. P., Montalescot, G., Macaya, C., Di Pasquale, G., Niemela, K., Ajani, A. E., White, H. D., Chrolavicius, S., Gao, P., Fox, K. A., Yusuf, S., & CURRENT-OASIS 7 trial investigators. (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, 376, 1233–1243.PubMedCrossRefGoogle Scholar
  11. 11.
    Saraff, K. Y., Steinhubl, S. R., Hsu, A. P., & Topol, E. J. (2006). Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention. J Am Coll Cardiol, 47, p36B [Abstract].Google Scholar
  12. 12.
    Ferreiro, J. L., Bhatt, D., Ueno, M., Bauer, D., & Angiolillo, D. J. (2013). Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013.10.043.Google Scholar
  13. 13.
    Salek, F. S. (2010). Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction. Pharmacotherapy, 30, 154e [Abstract].Google Scholar
  14. 14.
    Hochholzer, W., Trenk, D., Mega, J. L., Morath, T., Stratz, C., Valina, C. M., O'Donoghue, M. L., Bernlochner, I., Contant, C. F., Gou, J., Sabatine, M. S., Schömig, A., Neumann, F. J., Kastrati, A., Wiviott, S. D., & Sibbing, D. (2011). Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J, 162, 518–526.PubMedCrossRefGoogle Scholar
  15. 15.
    Bliden, K. P., Dichiara, J., Lawal, L., Singla, A., Antonino, M. J., Baker, B. A., Bailey, W. L., Tantry, U. S., & Gurbel, P. A. (2008). The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol, 52, 531–533.PubMedCrossRefGoogle Scholar
  16. 16.
    Ueno, M., Ferreiro, J. L., Desai, B., Tomasello, S. D., Tello-Montoliu, A., Capodanno, D., Capranzano, P., Kodali, M., Dharmashanker, K., Charlton, R. K., Bass, T. A., & Angiolillo, D. J. (2012). Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv, 5, 293–300.PubMedCrossRefGoogle Scholar
  17. 17.
    Gurbel, P. A., Bliden, K. P., Logan, D. K., Kereiakes, D. J., Lasseter, K. C., White, A., Angiolillo, D. J., Nolin, T. D., Maa, J. F., Bailey, W. L., Jakubowski, J. A., Ojeh, C. K., Jeong, Y. H., Tantry, U. S., & Baker, B. A. (2013). The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol, 62, 505–512.PubMedCrossRefGoogle Scholar
  18. 18.
    Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2009). Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res, 124, 588–591.PubMedCrossRefGoogle Scholar
  19. 19.
    Faber, M. S., & Fuhr, U. (2004). Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther, 76, 178–184.PubMedCrossRefGoogle Scholar
  20. 20.
    Washio, I., Maeda, M., Sugiura, C., Shiga, R., Yoshida, M., Nonen, S., Fujio, Y., & Azuma, J. (2011). Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos, 39, 1–3.PubMedCrossRefGoogle Scholar
  21. 21.
    CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329–1339.CrossRefGoogle Scholar
  22. 22.
    Shanker, G., Kontos, J. L., Eckman, D. M., Wesley-Farrington, D., & Sane, D. C. (2006). Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis, 22, 213–220.PubMedCrossRefGoogle Scholar
  23. 23.
    Wall, M. A., Johnson, J., Jacob, P., & Benowitz, N. L. (1988). Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health, 78, 699–701.PubMedCrossRefGoogle Scholar
  24. 24.
    Ueno, M., Ferreiro, J. L., Tomasello, S. D., Tello-Montoliu, A., Capodanno, D., Seecheran, N., Kodali, M., Dharmashankar, K., Desai, B., Charlton, R. K., Bass, T. A., & Angiolillo, D. J. (2011). Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv, 4, 905–912.PubMedCrossRefGoogle Scholar
  25. 25.
    Tello-Montoliu, A., Thano, E., Rollini, F., Patel, R., Wilson, R. E., Muñiz-Lozano, A., Franchi, F., Darlington, A., Desai, B., Guzman, L. A., Bass, T. A., & Angiolillo, D. J. (2013). Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Thromb Haemost, 110, 777–784.PubMedCrossRefGoogle Scholar
  26. 26.
    Gurbel, P. A., Bliden, K. P., Guyer, K., Aggarwal, N., & Tantry, U. S. (2007). Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res, 119, 563–570.PubMedCrossRefGoogle Scholar
  27. 27.
    Barua, R. S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., Margosan, D., & Ambrose, J. A. (2010). Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol, 30, 75–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Angiolillo, D. J., Capranzano, P., Desai, B., Shoemaker, S. B., Charlton, R., Zenni, M. M., Guzman, L. A., & Bass, T. A. (2009). Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res, 124, 318–322.PubMedCrossRefGoogle Scholar
  29. 29.
    Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004). Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract, 10, 307–312.PubMedCrossRefGoogle Scholar
  30. 30.
    Prodan, C. I., Joseph, P. M., Vincent, A. S., & Dale, G. L. (2007). Coated-platelet levels are influenced by smoking, aspirin, and selective serotonin reuptake inhibitors. J Thromb Haemost, 5, 2149–2151.PubMedCrossRefGoogle Scholar
  31. 31.
    Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007). Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 298, 2654–2664.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith, S. C., Jr., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Lloyd-Jones, D. M., Minissian, M., Mosca, L., Peterson, E. D., Sacco, R. L., Spertus, J., Stein, J. H., & Taubert, K. A. (2011). AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol, 58, 2432–2446.PubMedCrossRefGoogle Scholar
  33. 33.
    Tantcheva-Poór, I., Zaigler, M., Rietbrock, S., & Fuhr, U. (1999). Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasian using saliva-based caffeine test. Pharmacogenetics, 9, 131–144.PubMedGoogle Scholar
  34. 34.
    Park, K. W., Kang, S. H., Kang, J., Jeon, K. H., Park, J. J., Han, J. K., Koh, J. S., Lee, S. E., Yang, H. M., Lee, H. Y., Kang, H. J., Koo, B. K., Oh, B. H., Park, Y. B., & Kim, H. S. (2012). Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of ‘smokers' paradox’. Heart, 98, 1000–1006.PubMedCrossRefGoogle Scholar
  35. 35.
    Wennmalm, A., Benthin, G., Granström, E. F., Persson, L., Petersson, A. S., & Winell, S. (1991). Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation, 83, 1698–1704.PubMedCrossRefGoogle Scholar
  36. 36.
    Pamukcu, B., Oflaz, H., Onur, I., Cimen, A., & Nisanci, Y. (2011). Effects of cigarette smoking on platelet aggregation. Clin Appl Thromb Hemost, 17, E175–E180.PubMedCrossRefGoogle Scholar
  37. 37.
    Loke, W. M., Lam Mok Sing K., Lee, C. Y., Chong, W. L., Chew, S. E., Huang, H., Looi, W. F., Quek, A. M., Lim, E. C., Seet, R. C. (2012). Cyclooxygenase-1-mediated platelet reactivity in young male smokers. Clin Appl Thromb Hemost Dec 14. [Epub ahead of print]Google Scholar
  38. 38.
    Henry, P., Vermillet, A., Boval, B., Guyetand, C., Petroni, T., Dillinger, J. G., Sideris, G., Sollier, C. B., & Drouet, L. (2011). 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost, 105, 336–344.PubMedCrossRefGoogle Scholar
  39. 39.
    Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K. H., Easton, J. D., Hamm, C., Hu, T., Fox, K. A., & Topol, E. J. (2008). Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization. Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation, 118, 1705–1712.PubMedCrossRefGoogle Scholar
  40. 40.
    Angiolillo, D. J., Ueno, M., & Goto, S. (2010). Basic principles of platelet biology and clinical implications. Circ J, 74, 597–607.PubMedCrossRefGoogle Scholar
  41. 41.
    Cimmino, G., & Golino, P. (2013). Platelet biology and receptor pathways. J Cardiovasc Transl Res, 6, 299–309.PubMedCrossRefGoogle Scholar
  42. 42.
    Monroe, D. M., Hoffman, M., & Roberts, H. R. (2002). Platelets and thrombin generation. Arterioscler Thromb Vasc Biol, 22, 1381–1389.PubMedCrossRefGoogle Scholar
  43. 43.
    Leon, C., Ravanat, C., Freund, M., Cazenave, J. P., & Gachet, C. (2003). Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol, 23, 1941–1947.PubMedCrossRefGoogle Scholar
  44. 44.
    Norgard, N. B., Saya, S., Hann, C. L., Hennebry, T. A., Schechter, E., & Dale, G. L. (2008). Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. J Cardiovasc Pharmacol, 52, 536–539.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Fabiana Rollini
    • 1
  • Francesco Franchi
    • 1
  • Jung Rae Cho
    • 1
  • Christopher DeGroat
    • 1
  • Mona Bhatti
    • 1
  • Elisabetta Ferrante
    • 1
  • Ronakkumar Patel
    • 1
  • Andrew Darlington
    • 1
  • Antonio Tello-Montoliu
    • 1
  • Bhaloo Desai
    • 1
  • JoséLuis Ferreiro
    • 1
  • Ana Muniz-Lozano
    • 1
  • Martin M. Zenni
    • 1
  • Luis A. Guzman
    • 1
  • Theodore A. Bass
    • 1
  • Dominick J. Angiolillo
    • 1
    Email author
  1. 1.University of Florida College of Medicine-JacksonvilleJacksonvilleUSA

Personalised recommendations